ArticleOncoTargets and therapy2016

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.

Jianlin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.